Eyeworld

by Title Contact Name: email Heading Name title by Mitchell Weikert, MD Chief Medical Editor I remember my first substantial encounter with ASCRS, the 2002 Annual Meeting in Philadelphia, which I attended primarily to ac- cess some required training prior to the start of my cornea fellowship later that summer. Though I had been to the AAO Annual Meeting earlier that fall, I had not yet experienced such a large gathering devoted specifically to my area of interest, anterior segment surgery. Since that introduction, I have benefited from my ASCRS membership in countless ways. I've been able to expand my knowledge through year- round educational opportunities, such as live instructional and skills transfer courses, online webinars and journal clubs, and the vast CME resources available on the website. ASCRS has facilitated the communication of our research via paper and poster sessions at the Annual Meeting and through publication in the Journal of Cataract and Refrac- tive Surgery. My clinical practice is stronger due to the Society's advocacy efforts and ASOA's dedication to ad- vancing practice administration. Most importantly, I have been able to maximize my career fulfillment through the many world-renowned mentors, trusted colleagues, and close friends I have gained over the last 25 years. In addition to these direct membership benefits, I have been fortunate to serve on the Refractive Surgery and Cat- aract Clinical Committees and CME Advisory Committee, chair the Skills Transfer Committee, help plan the inaugu- ral ASCRS Live! meetings, participate in numerous sym- posia and wet labs, and serve on the Editorial Board and as the Cataract Editor for EyeWorld. In fact, almost every milestone in my career thus far has been tied to opportuni- ties provided by my involvement with ASCRS. In this spirit, I am honored and excited to assume the role of Chief Medical Editor of EyeWorld. As the publication that directly represents the broad ASCRS membership, EyeWorld is en- trusted with delivering content that is practical, timely, and relevant, directly addressing the topics of most concern to our readers. Lucky for us, these responsibilities rest on the shoulders of an exceptionally qualified and dedicated team led by Stacy Jablonski, Ellen Stodola, and Liz Hillman, who I've been indebted to for the last 13 years and on whom I'll now rely even more. EyeWorld also benefits from the expe- rience and acumen of the Editorial Board and our tireless SUMMER 2026 | EYEWORLD | 3 Thoughts as the new Chief Medical Editor Clareon ® PanOptix ® Pro Trifocal IOLs IMPORTANT PRODUCT INFORMATION CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician. INDICATIONS: The Clareon ® PanOptix ® Pro Trifocal IOLs include Clareon ® PanOptix ® Pro and Clareon ® PanOptix ® ProToric and are indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL. In addition, the Clareon ® PanOptix ® Pro Toric Trifocal IOL is indicated for the reduction of residual refractive astigmatism. WARNINGS/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Physicians should target emmetropia, and ensure that IOL centration is achieved. For the Clareon ® PanOptix ® Pro Toric Trifocal IOLs, the lens should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation. Some visual effects may be expected due to the superposition of focused and unfocused multiple images. These may include some perceptions of halos, radial lines around point sources of light (starbursts) under nighttime conditions, or glare, as well as other visual symptoms. As with other multifocal IOLs, there is a possibility that visual symptoms may be significant enough that the patient will request explant of the multifocal IOL. A reduction in contrast sensitivity as compared to that expected with a monofocal IOL may be experienced by some patients and may be more prevalent in low lighting conditions. Therefore, patients implanted with multifocal IOLs should exercise caution when driving at night or in poor visibility conditions. Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning). As with other multifocal IOLs, patients may need glasses when reading small print or looking at small objects. Posterior capsule opacification (PCO), may significantly affect the vision of patients with multifocal IOLs sooner in its progression than patients with monofocal IOLs. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon informing them of possible risks and benefits associated with the IOLs. ATTENTION: Reference the Directions for Use labeling for each IOL for a complete listing of indications, warnings and precautions. References: 1. Alcon data on file, 2025. REF-25218 2. Alcon data on file, 2024. REF-25221 3. Alcon data on file, 2015. REF-08546 © 2026 Alcon Inc. 05/26 US-CPR-2500093 continued on page 10

• Blank Page
• Blank Page (1)